Wells Fargo Initiates Coverage On Celcuity Inc. (CELC) [Yahoo! Finance]
Celcuity Inc. (CELC)
Last celcuity inc. earnings: 3/12 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
celcuity.com/home/investors
Company Research
Source: Yahoo! Finance
On December 12, 2025, TheFly reported that Wells Fargo started covering Celcuity Inc. (NASDAQ:CELC) with a $126 price target and an Overweight rating. According to the firm, Phase 1 data and results from the wild-type cohort have significantly reduced the risk associated with the impending VIKTORIA-1 PIK3CA mutant readout. Wells Fargo also stated that the current share price is not reflecting gedatolisib's market potential in breast cancer. Metastatic castration-resistant prostate cancer is an additional upside alternative. Separately, as it moves forward with accelerated launch preparations, Celcuity Inc. (NASDAQ:CELC) reported peak revenue potential for gedatolisib of $2.5 billion to $3 billion in the most recent quarter. The firm noted the release of top-line data from the PIK3CA wild-type group of the Phase III VIKTORIA-1 study and discussed progress on clinical and regulatory objectives. The PIK3CA mutant cohort wrapped up enrolling, and results are anticipated in late Q1 or
Show less
Read more
Impact Snapshot
Event Time:
CELC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CELC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CELC alerts
High impacting Celcuity Inc. news events
Weekly update
A roundup of the hottest topics
CELC
News
- Celcuity (CELC) Surges 662% in 2025 on Breast Cancer Treatment Trial Results [Yahoo! Finance]Yahoo! Finance
- Celcuity: After Stellar 2025, I Predict More Success In 2026 And Beyond [Seeking Alpha]Seeking Alpha
- How Investors Are Reacting To Celcuity (CELC) Gedatolisib's Phase 3 Breast Cancer Data And Safety Profile [Yahoo! Finance]Yahoo! Finance
- Celcuity (CELC): Fresh Phase 3 Breast Cancer Data Prompts Closer Look at Gedatolisib-Driven Valuation [Yahoo! Finance]Yahoo! Finance
- Celcuity (NASDAQ:CELC) was upgraded by analysts at Wells Fargo & Company to a "strong-buy" rating.MarketBeat
CELC
Earnings
- 11/12/25 - Beat
CELC
Sec Filings
- 1/16/26 - Form SCHEDULE
- 1/9/26 - Form 4
- 1/9/26 - Form S-3ASR
- CELC's page on the SEC website